About Bioline  All Journals  Testimonials  Membership  News

Zoological Research
Kunming Institute of Zoology, Chinese Academy of Sciences
ISSN: 2095-8137
Vol. 40, No. 5, 2019, pp. 349-357
Bioline Code: zr19037
Full paper language: English
Document type: Review Article
Document available free of charge

Zoological Research, Vol. 40, No. 5, 2019, pp. 349-357

 en Stem cell therapy for Parkinson’s disease using non-human primate models
Chen, Zhen-Zhen & Niu, Yu-Yu


Stem cell therapy (SCT) for Parkinson’s disease (PD) has received considerable attention in recent years. Non-human primate (NHP) models of PD have played an instrumental role in the safety and efficacy of emerging PD therapies and facilitated the translation of initiatives for human patients. NHP models of PD include primates with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) -induced parkinsonism, who are responsive to dopamine replacement therapies, similar to human PD patients. Extensive research in SCT has been conducted to better treat the progressive dopaminergic neurodegeneration that underlies PD. For effective application of SCT in PD, however, a number of basic parameters still need to be tested and optimized in NHP models, including preparation and storage of cells for engraftment, methods of transplantation, choice of target sites, and timelines for recovery. In this review, we discuss the current status of NHP models of PD in stem cell research. We also analyze the advances and remaining challenges for successful clinical translation of SCT for this persistent disease.

Stem cell therapy; Non-human primates; Parkinson’s disease

© Copyright 2019 - Editorial Office of Zoological Research, Kunming Institute of Zoology, Chinese Academy of Sciences
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil